JP2004531478A - アミノセラミド様化合物および治療目的での使用方法 - Google Patents

アミノセラミド様化合物および治療目的での使用方法 Download PDF

Info

Publication number
JP2004531478A
JP2004531478A JP2002562732A JP2002562732A JP2004531478A JP 2004531478 A JP2004531478 A JP 2004531478A JP 2002562732 A JP2002562732 A JP 2002562732A JP 2002562732 A JP2002562732 A JP 2002562732A JP 2004531478 A JP2004531478 A JP 2004531478A
Authority
JP
Japan
Prior art keywords
compound
patient
pharmaceutically acceptable
composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002562732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531478A5 (enExample
Inventor
ジェイムズ エー． シェイマン，
ノーマン エス． ラディン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan-Ann Arbor
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2004531478A publication Critical patent/JP2004531478A/ja
Publication of JP2004531478A5 publication Critical patent/JP2004531478A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2002562732A 2001-01-10 2002-01-10 アミノセラミド様化合物および治療目的での使用方法 Pending JP2004531478A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26094801P 2001-01-10 2001-01-10
US26219601P 2001-01-17 2001-01-17
PCT/US2002/000808 WO2002062777A2 (en) 2001-01-10 2002-01-10 Amino ceramide-like compounds and therapeutic methods of use
CA002454456A CA2454456A1 (en) 2001-01-10 2003-12-24 Amino ceramide-like compounds and therapeutic methods of use

Publications (2)

Publication Number Publication Date
JP2004531478A true JP2004531478A (ja) 2004-10-14
JP2004531478A5 JP2004531478A5 (enExample) 2006-01-05

Family

ID=34841311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002562732A Pending JP2004531478A (ja) 2001-01-10 2002-01-10 アミノセラミド様化合物および治療目的での使用方法

Country Status (6)

Country Link
US (1) US7335681B2 (enExample)
EP (1) EP1358172B1 (enExample)
JP (1) JP2004531478A (enExample)
BR (1) BR0206400A (enExample)
CA (2) CA2434028C (enExample)
WO (1) WO2002062777A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012162546A (ja) * 2005-01-26 2012-08-30 Allergan Inc 鎮痛活性および／または免疫賦活活性を有する３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピルアミンおよび関連化合物
JP2013531238A (ja) * 2010-06-20 2013-08-01 ゾラ バイオサイエンシーズ オサケ ユキチュア 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6855830B2 (en) 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
EP2211856A4 (en) 2007-11-29 2011-02-09 Hospital For Sick Children COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
US8741967B2 (en) 2007-12-12 2014-06-03 Children's Hospital & Research Center At Oakland Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
US20100248365A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
MY192644A (en) 2009-11-27 2022-08-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2021214771A1 (en) * 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1128951A (zh) * 1993-08-13 1996-08-14 生化学工业株式会社 治疗神经元疾病的药物
CA2192555C (en) * 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
US6511979B1 (en) 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
EP1384719A1 (en) * 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US6855830B2 (en) 2001-07-16 2005-02-15 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012162546A (ja) * 2005-01-26 2012-08-30 Allergan Inc 鎮痛活性および／または免疫賦活活性を有する３−ヘテロアリール−３−ヒドロキシ−２−アミノ−プロピルアミンおよび関連化合物
JP2013531238A (ja) * 2010-06-20 2013-08-01 ゾラ バイオサイエンシーズ オサケ ユキチュア 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー
JP2017129592A (ja) * 2010-06-20 2017-07-27 ゾラ バイオサイエンシーズ オサケ ユキチュア 冠状動脈疾患高リスク患者を認定するリピドームバイオマーカー
US10261101B2 (en) 2010-06-20 2019-04-16 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US10955427B2 (en) 2010-06-20 2021-03-23 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
US12270816B2 (en) 2010-06-20 2025-04-08 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients

Also Published As

Publication number Publication date
BR0206400A (pt) 2005-01-18
EP1358172A2 (en) 2003-11-05
CA2434028C (en) 2010-11-09
US20070072916A1 (en) 2007-03-29
CA2454456A1 (en) 2005-06-24
WO2002062777A3 (en) 2002-11-28
WO2002062777A2 (en) 2002-08-15
CA2434028A1 (en) 2002-08-15
EP1358172B1 (en) 2009-11-18
US7335681B2 (en) 2008-02-26
WO2002062777A9 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
US5945442A (en) Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) Amino ceramide-like compounds and therapeutic methods of use
US7253185B2 (en) Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) Amino ceramide - like compounds and therapeutic methods of use
Abe et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth.
US7148251B2 (en) Amino ceramide-like compounds and therapeutic methods of use
JP4564108B2 (ja) デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
Abe et al. Improved inhibitors of glucosylceramide synthase
US6696059B2 (en) Combination drug therapy for glycolipid storage diseases
WO2001004108A1 (en) Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) Amino ceramide-like compounds and therapeutic methods of use
JP2011505374A (ja) リソソーム障害を処置するための組成物および方法
US6890949B1 (en) Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) Amino ceramide-like compounds and therapeutic methods of use
Radin Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase
AU774960B2 (en) Amino ceramide-like compounds and therapeutic methods of use
AU2002249942B2 (en) Amino ceramide-like compounds and therapeutic methods of use
AU2002249942A1 (en) Amino ceramide-like compounds and therapeutic methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090526